Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV) - COPCOV trial

niversity of Oxford0 个研究点目标入组 10,000 人开始时间: 2020年4月29日最近更新: 2020年8月25日

试验速览

暂无简介。

•1.Participant is willing and able to give informed consent for participation in the study
•2.Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals
•3.Adults (exact age is dependent on countries) less than 70 years old at the time of consent). See Appendix F for UK specific information
•4.Not previously diagnosed with COVID-19
•5.Not currently symptomatic with an ARI
•6.Participant works in a facility where there are cases of either proven or suspected COVID-19
•7.Possesses an internet-enabled smartphone (Android or iOS)
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 38000
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 2000

•1. Hypersensitivity reaction to chloroquine, hydroxychloroquine or 4-aminoquinolines
•2. Contraindication to taking chloroquine as prophylaxis e.g. known epileptic, known creatinine clearance < 10 ml/min
•3. Already taking chloroquine, hydroxychloroquine or 4-aminoquinolines
•4. Taking a concomitant medication described in section 8.5
•5. Known retinal disease
•6. Inability to be followed up for the trial period
•7. Known prolonged QT syndrome (however ECG is not required at baseline)
•8. Prior diagnosis of porphyria
•9. Known pregnancy or women who are actively trying to become pregnant

发起方